J&J’s Consumer Woes Finally Subside As Pharma Continues Strong
This article was originally published in The Pink Sheet Daily
The multinational health care company reported significant growth in 2013 that largely was driven by its pharmaceutical division, but bolstered by the resurrection of its long-plagued consumer brands.
You may also be interested in...
Johnson & Johnson’s pharma unit posted strong sales growth in immunology and infectious disease, while its burgeoning oncology business is growing substantially.
Otsuka and Lundbeck’s newly approved long-acting antipsychotic Abilify Maintena enters a sub-sector of the anti-psychotic market dominated by Johnson & Johnson for the last decade, but the new competitor may be able to gain ground by helping to grow the patient population.
Johnson & Johnson’s Susan Nettesheim, the consumer group VP of toxicology and product stewardship, says the firm’s recent decision to reformulate its personal care products without or with reduced levels of formaldehyde-releaser preservatives boiled down to responding to what consumers want.